Miltefosine promotes IFN-γ-dominated anti-leishmanial immune response

Journal of Immunology

Volumn 182, Issue 11, 2009, Pages 7146-7154

  Wadhone, Pallavi ^a   Maiti, Moitrayee ^a   Agarwal, Reena ^a   Kamat, Vanita ^a   Martin, Sunil ^a   Saha, Bhaskar ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 12; MILTEFOSINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE C; STAT1 PROTEIN; ANTIPROTOZOAL AGENT; DRUG DERIVATIVE; INTERFERON RECEPTOR; PHOSPHORYLCHOLINE; STAT1 PROTEIN, HUMAN;

ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME PHOSPHORYLATION; IMMUNE RESPONSE; IMMUNOMODULATION; LEISHMANIA DONOVANI; LEISHMANIASIS; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TH1 CELL; TH2 CELL; ANIMAL; DRUG EFFECT; HELPER CELL; IMMUNITY; IMMUNOLOGY; MACROPHAGE; METABOLISM; MOUSE MUTANT; PARASITOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; IMMUNITY; INTERFERON-GAMMA; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGES; MICE; MICE, KNOCKOUT; PHOSPHORYLATION; PHOSPHORYLCHOLINE; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 67449123024     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803859     Document Type: Article

References (55)

1. Alvar, J., C. Camavate, B. Gutierrez-Solar, M. Jinenez, F. Laguna, R. Lopez-Velez, R. Molina, and J. Moreno. 1997. Leishmania and human immunodeficiency virus co-infection: the first 10 years. Clin. Microbiol. Rev. 10: 298-319. (Pubitemid 27196673)
2. Choi, C. M., and E. A. Lerner. 2002. Leishmaniasis: recognition and management with a focus on the immuno-compromised patient. Am. J. Clin. Dermatol. 3: 91-105.
3. Berhe, N., D. Wolday, A. Hailu, Y. Abraham, A. Ali, T. Gebre-Michael, P. Desjeux, A. Sonnerborg, H. Akuffo, and S. Britton. 1999. HIV viral load and response to anti-leishmanial chemotherapy in co-infected patients. AIDS 13: 1921-1925.
4. Unger, C., W. Damenz, E. A. Fleer, D. J. Kim, A. Breiser, P. Hilgard, J. Engel, G. Nagel, and H. Eibl. 1989. Hexadecylphosphocholine, a new ether lipid analogue: studies on the anti-neoplastic activity in vitro and in vivo. Acta Oncol. 28: 213-217. (Pubitemid 19159628)
5. Croft, S. L., R. A. Neal, W. Pendergast, and J. H. Chan. 1987. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem. Pharmacol. 36: 2633-2636.
6. Murray, H. W., and S. Delph-Etienne. 2000. Visceral leishmanicidal activity of hexadecyl-phosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J. Infect. Dis. 181: 795-799.
7. Sundar, S., F. Rosenkaimer, M. K. Makharia, A. K. Goyal, A. K. Mandal, A. Voss, P. Hilgard, and H. W. Murray. 1998. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352: 1821-1823. (Pubitemid 28550072)
8. Arthur, G., and R. Bittman. 1998. The inhibition of cell signaling pathways by anti-tumor ether lipids. Biochim. Biophys. Acta 1390: 85-102.
9. Berkovic, D., U. Grunwald, W. Menzel, C. Unger, W. Hiddemann, and E. A. Fleer. 1995. Effects of hexadecylphosphocholine on membrane phospholipid metabolism in human tumor cells. Eur. J. Cancer 31: 2080-2085.
10. Escobar, P., V. Yardley, and S. L. Croft. 2001. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob. Agents Chemother. 45: 1872-1875.
11. Zeisig, R., M. Rudolf, I. Eue, and D. Arndt. 1995. Influence of hexadecylphosphocholine on the release of tumor necrosis factor and nitroxide from peritoneal macrophages in vitro. J. Cancer Res. Clin. Oncol. 121: 69-75.
12. Hilgard, P., E. Kampherm, L. Nolan, J. Pohl, and T. Reissmann. 1991. Investigation into the immunological effects of miltefosine, a new anticancer agent under development. J. Cancer Res. Clin. Oncol. 117: 403-408.
13. Hochhuth, C. H., K. Vehmeyer, H. Eibl, and C. Unger. 1992. Hexadecylphosphocholine induces IFN-γ secretion and expression of GM-CSF mRNA in human mononuclear cells. Cell Immunol. 141: 161-168.
14. Eue, I. 2002. Hexadecylphosphocholine selectively up-regulates expression of intercellular adhesion molecule-1 and class-I major histocompatibility complex antigen in human monocytes. J. Exp. Ther. Oncol. 2: 333-336.
15. Constantinescu, C. S., B. D. Hondowicz, M. M. Elloso, M. Wysocka, G. Trinchieri, and P. Scott. 1998. The role of IL-12 in the maintenance of an established Th1 immune response in experimental leishmaniasis. Eur. J. Immunol. 28: 2227-2233.
16. Bogdan, C., M. Rollinghoff, and A. Diefenbach. 2000. The role of nitric oxide in innate immunity. Immunol. Rev. 173: 17-26.
17. Bhardwaj, N., L. E. Rosas, W. P. Lafuse, and A. R. Satoskar. 2005. Leishmania inhibits STAT1-mediated IFN-γ signaling in macrophages: increased tyrosine phosphorylation of dominant negative STAT1β by Leishmania mexicana. Int. J. Parasitol. 35: 75-82.
18. Saha, B., H. N. Roy, A. Pakrashi, R. N. Chakraborty, and S. Roy. 1991. Immunobiological studies in experimental visceral leishmaniasis, I: changes in lymphoid organs and their possible roles in pathogenesis. Eur. J. Immunol. 21: 577-581.
19. Awasthi, A., R. K. Mathur, A. A. Khan, B. N. Joshi, N. Jain, S. Sawant, D. Mitra, and B. Saha. 2003. CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response. J. Exp. Med. 197: 1037-1043.
20. Basak, S. K., B. Saha, A. Bhattacharya, and S. Roy. 1992. Immunobiological studies in experimental visceral leishmaniasis, II: adherent cell-mediated down-regulation of delayed-type hypersensitivity response and up-regulation of B cell activation. Eur. J. Immunol. 22: 2041-2045.
21. Bodas, M., N. Jain, A. Awasthi, B. Ramanamurthy, and B. Saha. 2006. IL-2 is a key cytokine that regulates susceptibility to Leishmania infection. J. Immunol. 177: 4636-4643.
22. Saha, B., D. M. Harlan, C. H. June, K. P. Lee, and R. Abe. 1996. Protection against lethal toxic shock by targeted disruption of the CD28 gene. J. Exp. Med. 183: 2675-2680.
23. Mathur, R. K., A. Awasthi, P. Wadhone, B. Ramanamurthy, and B. Saha. 2004. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat. Med. 10: 540-544. Erratum in: Nat. Med. 2004.10: 755.
24. Murugaiyan, G., R. Agrawal, G. C. Mishra, D. Mitra, and B. Saha. 2006. Functional dichotomy in CD40 reciprocally regulates effector T cell functions. J. Immunol. 177: 6642-6649. (Pubitemid 44715027)
25. Murugaiyan, G., R. Agrawal, G. C. Mishra, D. Mitra, and B. Saha. 2007. Differential CD40/CD40L expression results in counteracting anti-tumor immune responses. J. Immunol. 178: 2047-2055. (Pubitemid 46233401)
26. Saha, B., G. Das, H. Vohra, N. K. Ganguly, and G. C. Mishra. 1995. Macrophage- T cell interaction in experimental visceral leishmaniasis: failure to express costimulatory molecules on Leishmania-infected macrophages and its implication in the suppression of cell-mediated immunity. Eur. J. Immunol. 25: 2492-2498.
27. Blanchette, J., N. Racette, R. Faure, K. A. Siminovitch, and M. Olivier. 1999. Leishmania-induced increases in activation of macrophage SHP-1 tyrosine phosphatase are associated with impaired IFN-γ-triggered JAK2 activation. Eur. J. Immunol. 29: 3737-3744.
28. Ki, S. W., K. Kasahara, H. J. Kwon, J. Eishima, K. Takesako, J. A. Cooper, M. Yoshida, and S. Horinouchi. 1998. Identification of radicicol as an inhibitor of in vivo Ras/Raf interaction with the yeast two-hybrid screening system. J. Antibiot. 51: 936-944.
29. Ma, H. T., W. W. Lin, B. Zhao, W. T. Wu, W. Huang, Y. Li, N. L. Jones, and H. S. Kruth. 2006. Protein kinase C β and δ isoenzymes mediate cholesterol accumulation in PMA-activated macrophages. Biochem. Biophys. Res. Commun. 349: 214-220.
30. Scheid, M. P., R. W. Lauener, and V. Duronio. 1995. Role of phosphatidylinositol 3-OH-kinase activity in the inhibition of apoptosis in haemopoietic cells: phosphatidylinositol 3-OH-kinase inhibitors reveal a difference in signalling between interleukin-3 and granulocyte-macrophage colony stimulating factor. Biochem J. 312: 159-162.
31. Murray, H. W. 1997. Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis. J. Infect. Dis. 175: 1477-1479.
32. Engwerda, C. R., M. L. Murphy, S. E. Cotterell, S. C. Smelt, and P. M. Kaye. 1998. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur. J. Immunol. 28: 669-680.
33. Ahuja, S. S., R. L. Reddick, N. Sato, E. Montalbo, V. Kostecki, W. Zhao, M. J. Dolan, P. C. Melby, and S. K. Ahuja. 1999. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J. Immunol. 163: 890-897.
34. Chakkalath, H. R., and R. G. Titus. 1994. Leishmania major-parasitized macrophages augment Th2-type T cell activation. J. Immunol. 153: 4378-4387.
35. Olliaro, P. L., P. J. Guerin, S. Gerstl, A. A. Haaskjold, J. A. Rottingen, and S. Sundar. 2005. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect. Dis. 5: 763-774.
36. Murray, H. W., M. J. Oca, A. M. Granger, and R. D. Schreiber. 1989. Successful response to chemotherapy in experimental visceral leishmaniasis: requirement for T cells and effect of lymphokines. J. Clin. Invest. 83: 1254-1259.
37. Sundar, S., and M. Rai. 2005. Treatment of visceral leishmaniasis. Expert Opin. Pharmacother. 6: 2821-2829.
38. Croft, S. L., K. Seifert, and V. Yardley. 2006. Current scenario of drug development for leishmaniasis. Indian J. Med. Res. 123: 399-410.
39. + T-cell depletion in HIV infection: killed by friendly fire? Curr. HIV/AIDS Rep. 2: 16-23.
40. Paiardini, M., B. Cervasi, R. Dunham, B. Sumpter, H. Radziewicz, and G. Silvestri. 2004. Cell-cycle dysregulation in the immunopathogenesis of AIDS. Immunol. Res. 29: 253-268.
41. Chougnet, C. 2003. Role of CD40 ligand dysregulation in HIV-associated dysfunction of antigen-presenting cells. J. Leukocyte Biol. 74: 702-709.
42. Paris, C., P. M. Loiseau, C. Bories, and J. Breard. 2004. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 48: 852-859.
43. Rosas, L. E., H. M. Snider, J. Barbi, A. A. Satoskar, G. Lugo-Villarino, T. Keiser, T. Papenfuss, J. E. Durbin, D. Radzioch, L. H. Glimcher, and A. R. Satoskar. 2006. STAT1 and T-bet play distinct roles in determining outcome of visceral leishmaniasis caused by Leishmania donovani. J. Immunol. 177: 22-25.
44. Murphy, M. L., C. R. Engwerda, P. M. Gorak, and P. M. Kaye. 1997. B7-2 blockade enhances T cell responses to Leishmania donovani. J. Immunol. 159: 4460-4466.
45. Reiner, N. E., W. Ng, T. Ma, and W. R. McMaster. 1988. Kinetics of γ interferon binding and induction of major histocompatibility complex class II mRNA in Leishmania-infected macrophages. Proc. Natl. Acad. Sci. USA 85: 4330-4334.
46. + effector cells default to the Th2 pathway in interferon γ-deficient mice infected with Leishmania major. J. Exp. Med. 179: 1367-1371.
47. Valdrinez, M., C. Lonardoni, R. Momtchillo, and S. Jancar. 2000. Essential role of platelet-activating factor in the control of Leishmania amazonensis infection. Infect. Immun. 68: 6355-6361.
48. Santiago, H. C., M. F. B. Pires, D. G. Souza, E. Roffe, D. F. Cortes, W. L. Tafuri, M. M. Teixeira, and L. Q. Vieira. 2006. Platelet activating factor receptor-deficient mice present delayed interferon-γ upregualtion and high susceptibility to Leishmania amazonensis infection. Microbes Infect. 8: 2569-2577.
49. Cabrera-Serra, M. G., B. Valladares, and J. E. Pinero. 2008. In vivo activity of perifosine against Leishmania amazonensis. Acta Trop. 108: 20-25.
50. Lux, H., N. Heise, T. Klenner, D. Hart, and F. R. Opperdoes. 2000. Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol. Biochem. Parasitol. 111: 1-14.
51. Azzouz, S., M. Maache, M. F. Dos Santos, M. E. Sarciron, A. F. Petavy, and A. Osuna. 2006. Aspects of the cytological activity of edelfosine, miltefosine, and ilmofosine in Leishmania donovani. J. Parasitol. 92: 877-883.
52. Coghi, P., N. Vaiana, M. G. Pezzano, L. Rizzi, M. Kaiser, R. Brun, and S. Romeo. 2008. Parallel synthesis and anti-leishmanial activity of ether-linked phospholipids. Bioorg. Med. Chem. Lett. 18: 4658-4660.
53. Santa-Rita, R. M., A. Henriques-Pons, H. S. Barbosa, and S. L. de Castro. 2004. Effects of the lysophospholipid analogue edelfosine, ilmofosine and miltefosine against Leishmania amazonensis. J. Antimicrob. Chemother. 54: 704-710.
54. Escober, P., S. Matu, C. Marques, and S. L. Croft. 2002. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edel-fosine) and amphotericin B. Acta Trop. 81: 151-157.
55. Munoz-Martinez, F., C. Torres, S. Castanys, and F. Gamarro. 2008. The antitumor alkylphospholipid perifosine is internalized by an ATP-dependent translocase activity across plasma membrane of human KB carcinoma cells. Biochim. Biophys. Acta 1778: 530-540.